| Literature DB >> 23566489 |
Joan Riera1, Victoria Pons, Daniel Martinez-Puig, Carlos Chetrit, Josep A Tur, Antoni Pons, Franchek Drobnic.
Abstract
BACKGROUND: Strenuous exercise has been classically associated to immune-suppression and consequently to an increased risk of infections, especially at the upper respiratory tract. The administration of dietary nucleotides has been demonstrated useful to maintain the immune function in situations of stress and thus could be an appropriate strategy to counteract the decline of the immune function associated to strenuous exercise. The aim of the present study was to asses the impact of a specific nucleotide formulation (Inmunactive®) on the markers of immune function of athletes after a heavy exercise bout under cold conditions.Entities:
Year: 2013 PMID: 23566489 PMCID: PMC3626726 DOI: 10.1186/1550-2783-10-20
Source DB: PubMed Journal: J Int Soc Sports Nutr ISSN: 1550-2783 Impact factor: 5.150
Subjects characteristics and performance at baseline
| Age (yr) | 22.8 ± 5 | 21.9 ± 3 |
| Body mass (kg) | 70.7 ± 4.7 | 75.8 ± 3.25 |
| Body composition (% fat) | 11.6 ± 3.5 | 9.5 ±3.8 |
| VO2max (mL · kg-1 · min-1) | 45.8 ± 5.3 | 47.3 ± 7.0 |
VO2max = maximal oxygen uptake. Values are presented as means ± SE (n = 10).
No differences between groups were detected.
Figure 1Mean temperature and heart rate during exercise before and after 30 days of supplementation. Values are means ± SE (n = 10). P = Placebo; I = Inmunactive. Tm = Mean temperature; HR = Heart Rate.
Maximal physiological and performance values on exercise tests before and after 30 days of supplementation
| Skin temperature (°C) | 29.1 ± 0.4 | 29.4 ± 0.3 | 30.4 ± 0.6 | 29.4 ± 0.7 |
| Core temperature (°C) | 38.5 ± 0.1 | 38.5 ± 0.1 | 38.5 ± 0.1 | 38.2 ± 0.1 |
| Heart rate (bpm) | 176 ± 3 | 179 ± 3 | 171 ± 4 | 171 ± 3 |
| Lactate (mM) | 10.1 ± 0.9 | 9.9 ± 1.1 | 8.7 ± 0.6 | 7.7 ± 1.4 |
| Borg scale | 18.8 ± 0.1 | 18.6 ± 0.2 | 18 ± 0.4 | 17.9 ± 0.5 |
Values are means ± SE (n = 10). No significant differences across time within a group treatment or between groups at specified time point were detected.
Blood count during exercise tests before and after 30 days of supplementation
| Total leukocytes (109 · L-1) | | | | |
| Basal | 6.38 ± 0.53b | 6.10 ± 0.47b | 7.00 ± 0.71b | 5.25 ± 0.44b |
| 30 min | 6.34 ± 0.76b | 6.72 ± 0.93b | 6.83 ± 0.74b | 5.66 ± 0.72b |
| 150 min | 10.45 ± 1.19a | 9.86 ± 1.03a | 10.36 ± 0.86a | 8.32 ± 0.96ª |
| Neutrophils (109 · L-1) | | | | |
| Basal | 3.69 ± 0.35c | 3.27 ± 0.41b | 4.06 ± 0.43b | 2.98 ± 0.38b |
| 30 min | 4.30 ± 0.70b | 4.65 ± 0.87b | 4.30 ± 0.54b | 3.83 ± 0.70b |
| 150 min | 8.06 ± 0.89a | 7.80 ± 1.01a | 7.27 ± 0.59a | 7.17 ± 1.05ª |
| Lymphocytes (109 · L-1) | | | | |
| Basal | 2.03 ± 0.14ª | 2.03 ± 0.13ª | 2.12 ± 0.22ª | 1.73 ± 0.12ª |
| 30 min | 1.37 ± 0.09b | 1.39 ± 0.12b | 1.77 ± 0.17b | 1.44 ± 0.09b |
| 150 min | 1.68 ± 0.11b | 1.43 ± 0.11b | 2.27 ± 0.37ª* | 1.50 ± 0.07ab |
Values are means ± SE (n = 10). Different superscripts indicate significant differences across time within a group treatment. An asterisk indicates significant differences between groups at specified time point (P < 0.05).
Salivary IgA and PHA-Stimulated lymphocyte proliferation during exercise tests before and after 30 days of supplementation
| Salivary IgA (mg · L-1) | | | | |
| Basal | 1.87 ± 0.38 | 2.59 ± 1.16 | 2.32 ± 0.96 | 2.31 ± 0.61 |
| 150 min | 2.43 ± 1.06 | 2.13 ± 0.70 | 1.91 ± 0.54 | 1.35 ± 0.45 |
| PHA-Stimulated lymphocyte proliferation (cpm · 1000-1) | | | ||
| Basal | 29.3 ± 3.5 | 35.5 ± 4.4 | 29.1 ± 2.1 | 25.9 ± 3.9 |
| 24 h | 21.4 ± 3.6 | 35.9 ± 53.8* | 34.5 ± 5.4 | 20.6 ± 5.1* |
Values are means ± SE (n = 10). An asterisk indicates significant differences between groups at specified time point (P < 0.05).